Related Experiment Video

Updated: Oct 11, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K

Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell

T Gambichler1, C H Scheel1, J Reuther1,2

  • 1Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

Journal of the European Academy of Dermatology and Venereology : JEADV
|December 2, 2021
PubMed

Insights

Immune checkpoint inhibitors (ICI) offer hope for advanced cutaneous squamous cell carcinoma (cSCC). However, managing ICI-induced immune-related adverse events (irAEs) is complex in these patients due to comorbidities.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Immune checkpoint inhibitors (ICI) demonstrate significant efficacy in treating advanced cutaneous squamous cell carcinoma (cSCC).
  • ICI therapy can lead to immune-related adverse events (irAEs) affecting multiple organ systems.
  • Patients with advanced cSCC often present with unique challenges, including advanced age, comorbidities, and immunosuppression, complicating ICI use.

Purpose of the Study:

  • To review the management of anti-programmed cell death protein 1 (PD-1)-induced irAEs in patients with cSCC.
  • To highlight the specific clinical challenges encountered when managing irAEs in this patient population.

Main Methods:

  • Review of existing literature on ICI therapy and irAE management in cSCC.
  • Focus on the complexities arising from patient comorbidities and immunosuppressive states.

Main Results:

  • Management of irAEs in cSCC patients requires careful consideration of their underlying health status.
  • The presence of comorbidities and immunosuppression in advanced cSCC patients increases the complexity of ICI treatment and irAE management.

Conclusions:

  • ICI therapy is a valuable option for advanced cSCC, but requires tailored management strategies for irAEs.
  • Addressing the unique clinical challenges in cSCC patients is crucial for optimizing ICI outcomes and safety.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

636

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
725
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K